Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Int J Mol Sci. 2023 Feb 1;24(3):2762. doi: 10.3390/ijms24032762.
Mitochondrial ribosomal protein L7/L12 (MRPL12) is a member of the mitochondrial ribosomal proteins (MRPs). However, the biological function of MRPL12 in lung adenocarcinoma (LUAD) remains unclear. The expression and prognostic value of MRPL12 in LUAD were systematically analyzed using UALCAN, TIMER, HPA, Kaplan-Meier plotter, and GEPIA databases. The relationship between MRPL12 and immune infiltrates was investigated using TIMER and TISIDB databases. The clinical significance of MRPL12 in LUAD patients was validated using a tissue microarray (TMA). Cellular functional experiments were carried out to examine the influences of MRPL12 knockdown on cell proliferation, migration, and invasion. MRPL12 was significantly upregulated in LUAD samples, and high MRPL12 expression was correlated with worse prognosis. MRPL12 expression was markedly associated with immunomodulators, chemokines, and infiltration levels of multiple immune cells. Furthermore, TMA results confirm the upregulation of MRPL12 expression in LUAD, and MRPL12 was identified as an independent prognostic factor in LUAD patients. MRPL12 knockdown inhibited proliferation, migration, and invasion of LUAD cells. These data indicate that MRPL12 is a prognostic biomarker and correlated with immune infiltrates in LUAD. Therefore, MRPL12 shows potential as a therapeutic target for LUAD.
线粒体核糖体蛋白 L7/L12（MRPL12）是线粒体核糖体蛋白（MRPs）的成员。然而，MRPL12 在肺腺癌（LUAD）中的生物学功能尚不清楚。本研究通过 UALCAN、TIMER、HPA、Kaplan-Meier plotter 和 GEPIA 数据库系统分析了 MRPL12 在 LUAD 中的表达和预后价值。通过 TIMER 和 TISIDB 数据库研究了 MRPL12 与免疫浸润的关系。使用组织微阵列（TMA）验证了 MRPL12 在 LUAD 患者中的临床意义。进行细胞功能实验以研究 MRPL12 敲低对细胞增殖、迁移和侵袭的影响。MRPL12 在 LUAD 样本中明显上调，高表达与预后不良相关。MRPL12 表达与免疫调节剂、趋化因子和多种免疫细胞浸润水平显著相关。此外，TMA 结果证实了 LUAD 中 MRPL12 表达的上调，并且 MRPL12 是 LUAD 患者的独立预后因素。MRPL12 敲低抑制了 LUAD 细胞的增殖、迁移和侵袭。这些数据表明，MRPL12 是 LUAD 的预后生物标志物，并与 LUAD 中的免疫浸润相关。因此，MRPL12 显示出作为 LUAD 治疗靶点的潜力。
